Skip to main content
. 2019 Mar 18;2019(3):CD011269. doi: 10.1002/14651858.CD011269.pub3

Summary of findings 4. Bright white light therapy compared with infrared light therapy for prevention of SAD.

Bright white light therapy compared with infrared light therapy for prevention of SAD
Patient or population: all participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
 Settings: outpatient field study; participants chose when (between 6 am and 9 am) and where they would use the visors
 Intervention: bright white light therapy
 Comparison: infrared light therapy
Outcomes Risk in both groups Relative effect
 (95% CI) Number of participants
 (studies) Quality of the evidence
 (GRADE) Comments
Risk in this treatment group Risk in this treatment group
Infrared light therapy Bright white light therapy
Incidence of SAD (SIGH‐SAD score ≥ 20)
(follow‐up 26 weeks)
Study population RR 1.29
 (0.50 to 3.28) 29
 (1 RCT) ⊕⊝⊝⊝
 Very lowa,b  
333 per 1000 357 per 1000
Incidence of severe SAD (SIGH‐SAD‐SR (≥ 40))
(follow‐up 26 weeks)
Study population RR 1.07
 (0.07 to 15.54) 29
 (1 RCT) ⊕⊝⊝⊝
 Very lowa,b  
67 per 1000 71 per 1000
Overall discontinuation
(follow‐up 26 weeks)
Study population RR 1.33
 (0.35 to 5.13) 36
 (1 RCT) ⊕⊝⊝⊝
 Very lowa,b  
167 per 1000 222 per 1000
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio; SIGH‐SAD‐SR: Structured Interview Guide for the Hamilton Depression Rating Scale‐Seasonal Affective Disorders self‐rating version
GRADE Working Group grades of evidence
 High quality: further research is very unlikely to change our confidence in the estimate of effect
 Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
 Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
 Very low quality: we are very uncertain about the estimate

aDowngraded two levels because of severe risk of bias due to non‐blinding and unclear randomisation process and allocation concealment; no intention‐to‐treat analysis was reported, outcomes were self‐rated, compliance throughout study duration was not checked and participant characteristics were not reported comprehensively.
 bDowngraded one level because of small sample size (lack of power and random error could have influenced results).